Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Cetuximab for Patients With Advanced or Metastatic Chordoma

NCT05041127 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT05041127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05041127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Cetuximab for Patients With Advanced or Metastatic Chordoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 27, 2022
Completion date
September 1, 2028
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chordoma, metastatic chordoma, unresectable chordoma